Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.42 |
| ▸ | GMNN | O75496 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | THPO | P40225 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7870878 | 1.00 | LMNA (0.50) | LMNAMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL7875780 | 1.00 | LMNA (0.50) | LMNAMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL7875772 | 1.00 | LMNA (0.50) | LMNAMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL28430867 | 0.98 | LMNA (0.46) | LMNAMEN1KMT2AALDH1A1HSD17B10 | |
| Ethylene Glycol SCHEMBL23391403 | 0.95 | LMNA (0.50) | LMNAMEN1KMT2AALDH1A1HSD17B10 | |
| Ethylene Glycol SCHEMBL28947094 | 0.95 | LMNA (0.50) | LMNAMEN1KMT2AALDH1A1HSD17B10 | |
| Ethylene Glycol SCHEMBL28556296 | 0.95 | LMNA (0.50) | LMNAMEN1KMT2AALDH1A1HSD17B10 | |
| Ethylene Glycol SCHEMBL28776254 | 0.95 | LMNA (0.50) | LMNAMEN1KMT2AALDH1A1HSD17B10 | |
| Ethylene Glycol SCHEMBL23391391 | 0.95 | LMNA (0.50) | LMNAMEN1KMT2AALDH1A1HSD17B10 | |
| Ethylene Glycol SCHEMBL4353876 | 0.95 | LMNA (0.50) | LMNAMEN1KMT2AALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0483105-B2 | Solid drug-delivery devices employing fatty acid esters or fatty alcohol ethers of alkanediols as percutaneous absorption enhancers | ORTHO MCNEIL PHARM INC (US) | 2001-01-17 | — | — | EP | disclosed |
| EP-0272987-B1 | RESILIENT TRANSDERMAL DRUG-DELIVERY DEVICE AND COMPOSITIONS AND DEVICES EMPLOYING FATTY ACID ESTERS/ETHERS OR ALKANEDIOLS AS PERCUTANEOUS ABSORPTION ENHANCERS | CYGNUS THERAPEUTIC SYSTEMS (US) | 1993-03-24 | — | — | EP | disclosed |
| EP-0272918-B1 | DIFFUSION MATRIX FOR TRANSDERMAL DRUG ADMINISTRATION AND TRANSDERMAL DRUG DELIVERY DEVICES INCLUDING SAME | CYGNUS THERAPEUTIC SYSTEMS (US) | 1992-07-15 | — | — | EP | disclosed |
| EP-0483105-A1 | Solid drug-delivery devices employing fatty acid esters or fatty alcohol ethers of alkanediols as percutaneous absorption enhancers | CYGNUS THERAPEUTIC SYSTEMS (US) | 1992-04-29 | — | — | EP | disclosed |
| US-5006342-A | Resilient transdermal drug delivery device | CYGNUS CORPORATION (US) | 1991-04-09 | — | — | US | disclosed |
| US-4911916-A | Diffusion matrix for transdermal drug administration and transdermal drug delivery devices including same | CYGNUS RESEARCH CORPORATION (US) | 1990-03-27 | — | — | US | disclosed |
| US-4906463-A | Transdermal drug-delivery composition | CYGNUS RESEARCH CORPORATION (US) | 1990-03-06 | — | — | US | disclosed |
| EP-0272918-A2 | Diffusion matrix for transdermal drug administration and transdermal drug delivery devices including same | CYGNUS THERAPEUTIC SYSTEMS (US) | 1988-06-29 | — | — | EP | disclosed |
| EP-0272987-A2 | Resilient transdermal drug-delivery device and compositions and devices employing fatty acid esters/ethers or alkanediols as percutaneous absorption enhancers | CYGNUS THERAPEUTIC SYSTEMS (US) | 1988-06-29 | — | — | EP | disclosed |